SAM
PTGX icon

Silvercrest Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Silvercrest Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.05M Sell
47,931
-5,286
-10% -$468K 0.04% 428
2025
Q4 		$4.65M Hold
53,217
– – 0.03% 443
2025
Q3 		$3.54M Sell
53,217
-1,506
-3% -$85.6K 0.02% 470
2025
Q2 		$3.02M Hold
54,723
– – 0.02% 492
2025
Q1 		$2.65M Sell
54,723
-29,703
-35% -$1.24M 0.02% 503
2024
Q4 		$3.26M Sell
84,426
-828
-1% -$36.1K 0.02% 470
2024
Q3 		$3.84M Sell
85,254
-105,914
-55% -$4.28M 0.03% 410
2024
Q2 		$6.62M Buy
191,168
+2,425
+1% +$71K 0.05% 350
2024
Q1 		$5.46M Buy
188,743
+8,247
+5% +$224K 0.04% 377
2023
Q4 		$4.14M Buy
180,496
+34
+0% +$595 0.03% 403
2023
Q3 		$3.01M Buy
180,462
+52,265
+41% +$1.01M 0.02% 431
2023
Q2 		$3.54M Buy
128,197
+14,842
+13% +$371K 0.03% 417
2023
Q1 		$2.61M Sell
113,355
-127,390
-53% -$2.14M 0.02% 441
2022
Q4 		$2.63M Sell
240,745
-2,268
-0.9% -$19.1K 0.02% 431
2022
Q3 		$2.05M Buy
243,013
+128,254
+112% +$1.21M 0.02% 441
2022
Q2 		$908K Sell
114,759
-5,075
-4% -$61.4K 0.01% 580
2022
Q1 		$2.84M Buy
119,834
+1,119
+0.9% +$31.5K 0.02% 449
2021
Q4 		$4.06M Buy
118,715
+47,372
+66% +$1.5M 0.03% 411
2021
Q3 		$1.26M Sell
71,343
-48,048
-40% -$2.05M 0.01% 539
2021
Q2 		$5.36M Buy
+119,391
New +$3.94M 0.04% 379

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Silvercrest Asset Management's PTGX Position: Q1 2026 in Review

Silvercrest Asset Management reduced its Protagonist Therapeutics (PTGX) stake by 9.9% in Q1 2026, selling an estimated $468K and leaving 47,931 shares worth $5.05M. The position accounts for 0.04% of the portfolio, ranked #428.

Silvercrest Asset Management first reported a position in PTGX in Q2 2021 and has held it in 20 quarters since. The position peaked at $6.62M in Q2 2024. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Silvercrest Asset Management held 47,931 shares of Protagonist Therapeutics worth $5.05M as of Q1 2026.
  • Silvercrest Asset Management sold 5,286 Protagonist Therapeutics shares in Q1 2026, an estimated $468K.
  • Protagonist Therapeutics made up 0.04% of Silvercrest Asset Management's portfolio in Q1 2026, its #428 holding.
  • Silvercrest Asset Management first reported a position in Protagonist Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • Silvercrest Asset Management's Protagonist Therapeutics position peaked at $6.62M in Q2 2024.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Silvercrest Asset Management's 13F filing for Q1 2026, filed 15 May 2026.